Anti-Human IL13 Recombinant Antibody (Anrukinzumab) (CAT#: TAB-H05)

Figure 1 Visual predictive check for the final model stratified by dose.

Examples included is 200 mg i.v. (study 5, UC patients).

Hua, F., Ribbing, J., Reinisch, W., Cataldi, F., & Martin, S. (2015). A pharmacokinetic comparison of anrukinzumab, an anti‐IL‐13 monoclonal antibody, among healthy volunteers, asthma and ulcerative colitis patients. British journal of clinical pharmacology, 80(1), 101-109.

Figure 2 Concentration vs. time profiles of anrukinzumab given as multiple i.v. 200 mg doses to UC patients or non-UC subjects.

Hua, F., Ribbing, J., Reinisch, W., Cataldi, F., & Martin, S. (2015). A pharmacokinetic comparison of anrukinzumab, an anti‐IL‐13 monoclonal antibody, among healthy volunteers, asthma and ulcerative colitis patients. British journal of clinical pharmacology, 80(1), 101-109.

Figure 3 Effect of anrukinzumab compared with placebo on fold change in faecal calprotectin.

Reinisch, W., Panés, J., Khurana, S., Toth, G., Hua, F., Comer, G. M., ... & Zhu, H. (2015). Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study. Gut, 64(6), 894-900.

Figure 4 Median total IL-13 level versus time profile by treatment group.

Reinisch, W., Panés, J., Khurana, S., Toth, G., Hua, F., Comer, G. M., ... & Zhu, H. (2015). Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study. Gut, 64(6), 894-900.

Figure 1 Anti-Human IL13 Recombinant Antibody (TAB-H05) in ELISA

ELISA analysis of TAB-H05 was performed by coating with Recombinant Human IL13. Then blocked with BSA and incubated with TAB-H05. A HRP-conjugated goat anti-human IgG was used as the secondary antibody (1: 2000). Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.

Figure 2 Anti-Human IL13 Recombinant Antibody (TAB-H05) in WB

WB analysis of TAB-H05 was performed by loading with Recombinant Human IL13 onto a 12% Tris-HCl polyacrylamide gel. Proteins were transferred to a CN membrane and blocked with 5% skim milk for at least one hour. Membranes were probed with TAB-H05 and a HRP goat anti-human IgG (H+L) was used as the secondary antibody (1: 3000). Chemiluminescent detection was performed.

Figure 3 Anti-Human IL13 Recombinant Antibody (TAB-H05) in DB

DB analysis of TAB-H05 was performed by coating with Recombinant Human IL13.
TAB-H05 incubation concentration: 2 μg/mL.
HRP-conjugated goat anti-human IgG (H+L) secondary antibody (1: 3000)
NC: Negative control, PC: Positive control